Overview

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Pieris Pharmaceuticals, Inc.

Treatments:

Paclitaxel
Ramucirumab
Tucatinib